Olson BM - Search Results

1

The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer.

Olson BM, Johnson LE, McNeel DG. Olson BM, et al. Cancer Immunol Immunother. 2013 Mar;62(3):585-96. doi: 10.1007/s00262-012-1363-9. Epub 2012 Oct 30. Cancer Immunol Immunother. 2013. PMID: 23108626 Free PMC article.

2

Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer.

Olson BM, McNeel DG. Olson BM, et al. Prostate. 2007 Dec 1;67(16):1729-39. doi: 10.1002/pros.20652. Prostate. 2007. PMID: 17879963

3

HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.

Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG. Olson BM, et al. Cancer Immunol Immunother. 2010 Jun;59(6):943-53. doi: 10.1007/s00262-010-0820-6. Epub 2010 Feb 6. Cancer Immunol Immunother. 2010. PMID: 20140431 Free PMC article.

4

DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer.

Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, McNeel DG. Becker JT, et al. Among authors: olson bm. J Immunother. 2010 Jul-Aug;33(6):639-47. doi: 10.1097/CJI.0b013e3181dda23e. J Immunother. 2010. PMID: 20551832 Free PMC article. Clinical Trial.

5

CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells.

Olson BM, McNeel DG. Olson BM, et al. Cancer Immunol Immunother. 2011 Jun;60(6):781-92. doi: 10.1007/s00262-011-0987-5. Epub 2011 Feb 25. Cancer Immunol Immunother. 2011. PMID: 21350948 Free PMC article.

6

Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade.

Olson BM, Jankowska-Gan E, Becker JT, Vignali DA, Burlingham WJ, McNeel DG. Olson BM, et al. J Immunol. 2012 Dec 15;189(12):5590-601. doi: 10.4049/jimmunol.1201744. Epub 2012 Nov 14. J Immunol. 2012. PMID: 23152566 Free PMC article.

7

Sipuleucel-T: immunotherapy for advanced prostate cancer.

Olson BM, McNeel DG. Olson BM, et al. Open Access J Urol. 2011 May 3;3:49-60. doi: 10.2147/OAJU.S13069. Open Access J Urol. 2011. PMID: 24198636 Free PMC article. Review.

8

Preclinical and clinical development of DNA vaccines for prostate cancer.

Colluru VT, Johnson LE, Olson BM, McNeel DG. Colluru VT, et al. Among authors: olson bm. Urol Oncol. 2016 Apr;34(4):193-204. doi: 10.1016/j.urolonc.2013.09.014. Epub 2013 Dec 12. Urol Oncol. 2016. PMID: 24332642 Free PMC article. Review.

9

DNA Vaccines for Prostate Cancer.

McNeel DG, Becker JT, Johnson LE, Olson BM. McNeel DG, et al. Among authors: olson bm. Curr Cancer Ther Rev. 2012 Nov 1;8(4):254-263. doi: 10.2174/157339412804143113. Curr Cancer Ther Rev. 2012. PMID: 24587772 Free PMC article.

10

Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer.

McNeel DG, Becker JT, Eickhoff JC, Johnson LE, Bradley E, Pohlkamp I, Staab MJ, Liu G, Wilding G, Olson BM. McNeel DG, et al. Among authors: olson bm. Clin Cancer Res. 2014 Jul 15;20(14):3692-704. doi: 10.1158/1078-0432.CCR-14-0169. Epub 2014 May 21. Clin Cancer Res. 2014. PMID: 24850844 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

57 results

Search Page

Filters